Sight Sciences, Inc., (SGHT): Price and Financial Metrics
SGHT Price/Volume Stats
| Current price | $7.48 | 52-week high | $15.30 |
| Prev. close | $7.52 | 52-week low | $5.35 |
| Day low | $7.45 | Volume | 130,600 |
| Day high | $8.13 | Avg. volume | 121,452 |
| 50-day MA | $9.32 | Dividend yield | N/A |
| 200-day MA | $9.61 | Market Cap | 362.48M |
SGHT Stock Price Chart Interactive Chart >
SGHT POWR Grades
- Sentiment is the dimension where SGHT ranks best; there it ranks ahead of 95.22% of US stocks.
- The strongest trend for SGHT is in Growth, which has been heading up over the past 179 days.
- SGHT's current lowest rank is in the Momentum metric (where it is better than 15.05% of US stocks).
SGHT Stock Summary
- SGHT's went public 1.86 years ago, making it older than merely 4.81% of listed US stocks we're tracking.
- SGHT's price/sales ratio is 5.92; that's higher than the P/S ratio of 82.23% of US stocks.
- As for revenue growth, note that SGHT's revenue has grown 36.36% over the past 12 months; that beats the revenue growth of 82.54% of US companies in our set.
- Stocks that are quantitatively similar to SGHT, based on their financial statements, market capitalization, and price volatility, are EAR, DUOT, STIM, TALK, and EKSO.
- To dig deeper into the stock's financial statements, go to SGHT's page on browse-edgar?action=getcompany&CIK=0001531177.
SGHT Valuation Summary
- SGHT's EV/EBIT ratio is -4.1; this is 134.17% lower than that of the median Healthcare stock.
- SGHT's price/earnings ratio has moved up 38.2 over the prior 23 months.
Below are key valuation metrics over time for SGHT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SGHT | 2023-05-23 | 5.8 | 3.0 | -5.5 | -4.1 |
| SGHT | 2023-05-22 | 6.0 | 3.1 | -5.6 | -4.2 |
| SGHT | 2023-05-19 | 6.1 | 3.2 | -5.8 | -4.4 |
| SGHT | 2023-05-18 | 6.4 | 3.3 | -6.1 | -4.7 |
| SGHT | 2023-05-17 | 6.2 | 3.2 | -5.8 | -4.4 |
| SGHT | 2023-05-16 | 6.3 | 3.3 | -6.0 | -4.6 |
SGHT Price Target
For more insight on analysts targets of SGHT, see our SGHT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $43.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Sight Sciences, Inc., (SGHT) Company Bio
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest SGHT News From Around the Web
Below are the latest news stories about SIGHT SCIENCES INC that investors may wish to consider to help them evaluate SGHT as an investment opportunity.
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System TechnologyRetrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 monthsSustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted through 24 monthsConfirmed safety and efficacy of OMNI Surgical System technology in both standalone and combination cataract proceduresLongest published multicenter clinical results of OMNI Surgical Syste |
How Much Upside is Left in Sight Sciences, Inc. (SGHT)? Wall Street Analysts Think 38.78%The average of price targets set by Wall Street analysts indicates a potential upside of 38.8% in Sight Sciences, Inc. (SGHT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® RegistryPatients undergoing procedures enabled with OMNI® Surgical System technology experienced a greater average reduction in IOP-lowering medication usage compared to other MIGS procedures or cataract surgery aloneMENLO PARK, Calif., May 06, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative technology that enables procedures intended to improve patients' lives, today announced the results from a 12-month re |
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue EstimatesSight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Sight Sciences Reports First Quarter 2023 Financial Results and Reaffirms Guidance for Full Year 2023MENLO PARK, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported financial results for the first quarter ended March 31, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights Generated first quarter revenue of $18.8 million, an increase of 26% compared to the |
SGHT Price Returns
| 1-mo | -25.20% |
| 3-mo | -28.08% |
| 6-mo | -38.03% |
| 1-year | -21.51% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -38.74% |
| 2022 | -30.51% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...